Mounjaro, which was approved for diabetes in May 2022 (and for weight loss under the name Zepbound in November 2023), reached 370,203 Medicare beneficiaries in 2023
But these two treatments are frequently contemplated by individuals who want to improve their overall health and maintain control of their weight
Is the combination synergistic, according to the article
Our Approach What sets Aspire Rejuvenation apart is the time we take to understand your health and your goals
Published Phase 2 data (NEJM, 2023) showed retatrutide achieving up to 24.2% body weight reduction over 48 weeks and significant hepatic fat reduction, supporting research into obesity, NAFLD/MASH, and insulin resistance models
He adds his wife gained back 4 kg soon after they stopped the drug